14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
PCVX vs LEGN: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Legend Biotech Corporation (LEGN) is the stronger overall head-to-head candidate over Vaxcyte, Inc. (PCVX) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). PCVX carries a Unified Composite Score of 47.3/100 (HOLD) at $62.02 (N/M Forward P/E, 0.0% operating margin), whereas LEGN carries 42.8/100 (HOLD) at $16.45 (27.5x Forward P/E, 2.8% operating margin).
Composite vs. Pillar Nuance: While PCVX currently prints a higher short-term Unified Composite Score (47.3/100 HOLD vs. LEGN 42.8/100 HOLD), LEGN captures the overall institutional head-to-head verdict (5–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (2.8% vs. 0.0% operating margin) and revenue trajectory (+32.0% vs. +0.0% YoY).
Technical & Structure Timing Caution: PCVX trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 47.2); meanwhile LEGN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on PCVX vs LEGN. Trailing 12-month operating profitability (PCVX 0.0% vs LEGN 2.8%) and valuation multiples (PCVX N/M vs LEGN 27.5x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $3.6B market capitalization and 2.8% operating margin.
OpEx & R&D Reinvestment54.2% of Rev ($736M)
90D Engineering Disclosures0 Published
Investor FAQ PCVX vs LEGN Key Questions & Quantitative Answers
As of Nov 16, 2026, Legend Biotech Corporation (LEGN) is the stronger overall head-to-head candidate over Vaxcyte, Inc. (PCVX) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). PCVX carries a Unified Composite Score of 47.3/100 (HOLD) at $62.02 (N/M Forward P/E, 0.0% operating margin), whereas LEGN carries 42.8/100 (HOLD) at $16.45 (27.5x Forward P/E, 2.8% operating margin). Composite vs. Pillar Nuance: While PCVX currently prints a higher short-term Unified Composite Score (47.3/100 HOLD vs. LEGN 42.8/100 HOLD), LEGN captures the overall institutional head-to-head verdict (5–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (2.8% vs. 0.0% operating margin) and revenue trajectory (+32.0% vs. +0.0% YoY). Technical & Structure Timing Caution: PCVX trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 47.2); meanwhile LEGN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
LEGN leads the Growth & Scale pillar: PCVX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with LEGN at +32.0% YoY revenue growth and +0.0% YoY earnings growth on $1.36B TTM revenue (57.0% gross margin, 2.8% operating margin). On trailing 12-month operating scale, PCVX generates N/A in USD-normalized revenue versus $1.36B for LEGN. In operating R&D and SG&A reinvestment, PCVX deploys N/A (0 90-day corporate R&D disclosures) versus 54.2% of Rev ($736M) (0 disclosures) for LEGN.
LEGN screens cheaper on headline valuation multiples. PCVX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas LEGN trades at 27.5x Forward P/E, 23.0x Trailing P/E, N/M PEG, and 2.6x EV/Revenue (3.7% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PCVX (-42.7% ROE) versus LEGN (-0.0% ROE) capital efficiency.
In options market volatility and institutional positioning, PCVX carries 52.2% implied volatility (10th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.28β · 57% Vol realized risk). By comparison, LEGN carries 42.4% implied volatility (24th %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.65β · 82% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.